EMEA (Europe, Middle East and Africa) ALL Vaccine Market Report 2017

Published by: | Published Date: April, 2017 | Number of pages: 131

$4,099$8,198

This report studies the ALL Vaccine market status and outlook of EMEA and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in EMEA and major countries, and splits the ALL Vaccine market by product type and applications/end industries.

The global ALL Vaccine market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

EMEA also play important roles in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of XX. EMEA will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

Geographically, this report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of ALL Vaccine in these regions, from 2012 to 2022 (forecast), covering
Europe covers Germany, France, UK, Russia, Italy and Benelux;
Middle East includes Saudi Arabia, Israel, UAE and Iran;
Africa includes South Africa, Nigeria, Egypt and Algeria.

The major players/manufacturers in EMEA market include Pfizer, Inc., Glaxosmithkline, PLC., Merck & Co., Inc., Novarits, Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Inc., Johnson & Johnson, Medimmune, LLC. (A Subsidiary of Astrazeneca), Astellas Pharma Inc., Mitsubishi Tanabe, Dynavax Technologies, Novavax,

On the basis of product, the ALL Vaccine market is primarily split into
Vaccinia
Measles, mumps, rubella
Varicella
Influenza
Rotavirus
Zoster
Yellow Fever
Polio
Hepatitis A
Rabies
BCG
Diphtheria, tetanus
Hepatitis B
Haemophilus influenzae type b
Pertussis
Human papillomavirus
Meningococcal
Pneumococcal

On the basis on the end users/applications, this report covers
For Adult
For Child

Clear
SKU: QY231379 Category:
Table of Contents

EMEA (Europe, Middle East and Africa) ALL Vaccine Market Report 2017
1 ALL Vaccine Overview
1.1 Product Overview and Scope of ALL Vaccine
1.2 Classification of ALL Vaccine by Product Category
1.2.1 EMEA ALL Vaccine Sales (K Units) Comparison by Types (2012-2022)
1.2.2 EMEA ALL Vaccine Sales Market Share (%) by Types in 2016
1.2.3 Vaccinia
1.2.4 Measles, mumps, rubella
1.2.5 Varicella
1.2.6 Influenza
1.2.7 Rotavirus
1.2.8 Zoster
1.2.9 Yellow Fever
1.2.10 Polio
1.2.11 Hepatitis A
1.2.12 Rabies
1.2.13 BCG
1.2.14 Diphtheria, tetanus
1.2.15 Hepatitis B
1.2.16 Haemophilus influenzae type b
1.2.17 Pertussis
1.2.18 Human papillomavirus
1.2.19 Meningococcal
1.2.20 Pneumococcal
1.3 EMEA ALL Vaccine Market by Applications/End Users
1.3.1 EMEA ALL Vaccine Sales (K Units) and CAGR (%) Comparison by Applications (2012-2022)
1.3.2 For Adult
1.3.3 For Child
1.4 EMEA ALL Vaccine Market Overview by Regions
1.4.1 EMEA ALL Vaccine Revenue (Million USD) Comparison by Regions (2012-2022)
1.4.2 Europe ALL Vaccine Status and Prospect (2012-2022)
1.4.3 Middle East ALL Vaccine Status and Prospect (2012-2022)
1.4.4 Africa ALL Vaccine Status and Prospect (2012-2022)
1.5 EMEA Market Size (Sales and Revenue) of ALL Vaccine (2012-2022)
1.5.1 EMEA ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2022)
1.5.2 EMEA ALL Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
2 EMEA ALL Vaccine Competition by Manufacturers/Players/Suppliers, Regions, Type and Application
2.1 EMEA ALL Vaccine Market Competition by Players/ Manufacturers
2.1.1 EMEA ALL Vaccine Sales (K Units) and Market Share of Major Players (2012-2017)
2.1.2 EMEA ALL Vaccine Revenue (Million USD) and Market Share (%) by Players (2012-2017)
2.1.3 EMEA ALL Vaccine Sale Price (USD/Unit) by Players (2012-2017)
2.2 EMEA ALL Vaccine Sales and Revenue by Type/Product Category
2.2.1 EMEA ALL Vaccine Sales (K Units) and Market Share (%) by Type (2012-2017)
2.2.2 EMEA ALL Vaccine Revenue (Million USD) and Market Share (%) by Type (2012-2017)
2.2.3 EMEA ALL Vaccine Sale Price (USD/Unit) by Type (2012-2017)
2.3 EMEA ALL Vaccine (Volume) by Application
2.4 EMEA ALL Vaccine Sales and Revenue by Regions
2.4.1 EMEA ALL Vaccine Sales (K Units) and Market Share (%) by Regions (2012-2017)
2.4.2 EMEA ALL Vaccine Revenue (Million USD) and Market Share (%) by Regions (2012-2017)
2.4.3 EMEA ALL Vaccine Sales Price (USD/Unit) by Regions (2012-2017)
3 Europe ALL Vaccine (Sales, Revenue and Price), by Players, Countries, Type and Application
3.1 Europe ALL Vaccine Sales (K Units) and Revenue (Million USD) (2012-2017)
3.1.1 Europe ALL Vaccine Sales (K Units) and Growth Rate (2012-2017)
3.1.2 Europe ALL Vaccine Revenue (Million USD) and Growth Rate (%) (2012-2017)
3.2 Europe ALL Vaccine Sales (K Units) and Market Share (%) by Type
3.3 Europe ALL Vaccine Sales (K Units) and Market Share (%) by Applications
3.4 Europe ALL Vaccine Sales (K Units) and Revenue (Million USD) by Countries
3.4.1 Europe ALL Vaccine Sales (K Units) by Countries (2012-2017)
3.4.2 Europe ALL Vaccine Revenue by Countries (2012-2017)
3.4.3 Germany ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
3.4.4 France ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
3.4.5 UK ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
3.4.6 Russia ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
3.4.7 Italy ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
3.4.8 Benelux ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
4 Middle East ALL Vaccine (Sales, Revenue and Price), by Players, Countries, Type and Application
4.1 Middle East ALL Vaccine Sales and Revenue (2012-2017)
4.1.1 Middle East ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
4.1.2 Middle East ALL Vaccine Revenue (Million USD) and Growth Rate (%) (2012-2017)
4.2 Middle East ALL Vaccine Sales (K Units) and Market Share (%) by Type
4.3 Middle East ALL Vaccine Sales (K Units) and Market Share (%) by Applications
4.4 Middle East ALL Vaccine Sales (K Units) and Revenue (Million USD) by Countries (2012-2017)
4.4.1 Middle East ALL Vaccine Sales (K Units) by Countries (2012-2017)
4.4.2 Middle East ALL Vaccine Revenue by Countries (2012-2017)
4.4.3 Saudi Arabia ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
4.4.4 Israel ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
4.4.5 UAE ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
4.4.6 Iran ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
5 Africa ALL Vaccine (Sales, Revenue and Price), by Players, Countries, Type and Application
5.1 Africa ALL Vaccine Sales and Revenue (2012-2017)
5.1.1 Africa ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
5.1.2 Africa ALL Vaccine Revenue (Million USD) and Growth Rate (%) (2012-2017)
5.2 Africa ALL Vaccine Sales (K Units) and Market Share (%) by Type
5.3 Africa ALL Vaccine Sales (K Units) and Market Share (%) by Applications
5.4 Africa ALL Vaccine Sales (K Units) and Revenue (Million USD) by Countries (2012-2017)
5.4.1 Africa ALL Vaccine Sales (K Units) by Countries (2012-2017)
5.4.2 Africa ALL Vaccine Revenue by Countries (2012-2017)
5.4.3 South Africa ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
5.4.4 Nigeria ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
5.4.5 Egypt ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
5.4.6 Algeria ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
6 EMEA ALL Vaccine Manufacturers/Players Profiles and Sales Data
6.1 Pfizer, Inc.
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 ALL Vaccine Product Types, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Pfizer, Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Glaxosmithkline, PLC.
6.2.1 Company Basic Information, Manufacturing Base and Competitors
6.2.2 ALL Vaccine Product Types, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Glaxosmithkline, PLC. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Merck & Co., Inc.
6.3.1 Company Basic Information, Manufacturing Base and Competitors
6.3.2 ALL Vaccine Product Types, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Merck & Co., Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Novarits
6.4.1 Company Basic Information, Manufacturing Base and Competitors
6.4.2 ALL Vaccine Product Types, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Novarits ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Sanofi Pasteur
6.5.1 Company Basic Information, Manufacturing Base and Competitors
6.5.2 ALL Vaccine Product Types, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Sanofi Pasteur ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
6.5.4 Main Business/Business Overview
6.6 CSL Limited
6.6.1 Company Basic Information, Manufacturing Base and Competitors
6.6.2 ALL Vaccine Product Types, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 CSL Limited ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Emergent Biosolutions, Inc.
6.7.1 Company Basic Information, Manufacturing Base and Competitors
6.7.2 ALL Vaccine Product Types, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Emergent Biosolutions, Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
6.7.4 Main Business/Business Overview
6.8 Johnson & Johnson
6.8.1 Company Basic Information, Manufacturing Base and Competitors
6.8.2 ALL Vaccine Product Types, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) Johnson & Johnson (2012-2017)
6.8.4 Main Business/Business Overview
6.9 Medimmune, LLC. (A Subsidiary of Astrazeneca)
6.9.1 Company Basic Information, Manufacturing Base and Competitors
6.9.2 ALL Vaccine Product Types, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 Medimmune, LLC. (A Subsidiary of Astrazeneca) ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
6.9.4 Main Business/Business Overview
6.10 Astellas Pharma Inc.
6.10.1 Company Basic Information, Manufacturing Base and Competitors
6.10.2 ALL Vaccine Product Types, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Astellas Pharma Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
6.10.4 Main Business/Business Overview
6.11 Mitsubishi Tanabe
6.12 Dynavax Technologies
6.13 Novavax
7 ALL Vaccine Manufacturing Cost Analysis
7.1 ALL Vaccine Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of ALL Vaccine
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 ALL Vaccine Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of ALL Vaccine Major Manufacturers in 2016
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 EMEA ALL Vaccine Market Forecast (2017-2022)
11.1 EMEA ALL Vaccine Sales, Revenue and Price Forecast (2017-2022)
11.1.1 EMEA ALL Vaccine Sales (K Units) and Growth Rate (%) Forecast (2017-2022)
11.1.2 EMEA ALL Vaccine Revenue (Million USD) and Growth Rate (%) Forecast (2017-2022)
11.1.3 EMEA ALL Vaccine Price (USD/Unit) and Trend Forecast (2017-2022)
11.2 EMEA ALL Vaccine Sales (K Units) and Revenue (Million USD) and Growth Rate (%) Forecast by Regions (2017-2022)
11.3 Europe ALL Vaccine Sales (K Units) and Revenue (Million USD) and Growth Rate (%) Forecast by Regions (2017-2022)
11.4 Middle East ALL Vaccine Sales (K Units) and Revenue (Million USD) and Growth Rate (%) Forecast by Regions (2017-2022)
11.5 Africa ALL Vaccine Sales (K Units) and Revenue (Million USD) and Growth Rate (%) Forecast by Regions (2017-2022)
11.6 EMEA ALL Vaccine Sales Forecast by Type (2017-2022)
11.7 EMEA ALL Vaccine Sales Forecast by Application (2017-2022)
12 Research Findings and Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer

Request Data
List of Tables and Figures

Table EMEA Market ALL Vaccine Revenue (Million USD) Comparison by Regions 2012-2022
Table EMEA ALL Vaccine Sales (K Units) and Revenue (Million USD) Market Split by Product Type
Table EMEA ALL Vaccine Sales (K Units) by Application (2016-2022)
Figure Product Picture of ALL Vaccine
Figure EMEA ALL Vaccine Sales Market Share (%) by Types in 2016
Figure Vaccinia Product Picture
Figure Measles, mumps, rubella Product Picture
Figure Varicella Product Picture
Figure Influenza Product Picture
Figure Rotavirus Product Picture
Figure EMEA Sales Market Share (%) of ALL Vaccine by Applications in 2016
Figure For Adult Examples
Figure For Child Examples
Figure Europe ALL Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East ALL Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa ALL Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2022)
Figure EMEA ALL Vaccine Revenue (Million USD) and Growth Rate (2012-2022)
Table EMEA ALL Vaccine Sales (K Units) of Major Players (2012-2017)
Table EMEA ALL Vaccine Sales Market Share (%) by Players (2012-2017)
Figure 2016 ALL Vaccine Sales Market Share (%) by Players
Figure 2017 ALL Vaccine Sales Market Share (%) by Players
Table EMEA ALL Vaccine Revenue (Million USD) by Players (2012-2017)
Table EMEA ALL Vaccine Revenue Market Share (%) by Players (2012-2017)
Table 2016 EMEA ALL Vaccine Revenue Market Share (%) by Players
Table 2017 EMEA ALL Vaccine Revenue Market Share (%) by Players
Table EMEA ALL Vaccine Sale Price (USD/Unit) by Players (2012-2017)
Table EMEA ALL Vaccine Sales (K Units) and Market Share (%) by Type (2012-2017)
Table EMEA ALL Vaccine Sales Market Share (%) by Type (2012-2017)
Figure Sales Market Share (%) of ALL Vaccine by Type (2012-2017)
Figure EMEA ALL Vaccine Sales Market Share (%) by Type in 2016
Table EMEA ALL Vaccine Revenue (Million USD) and Market Share (%) by Type (2012-2017)
Table EMEA ALL Vaccine Revenue Market Share (%) by Type (2012-2017)
Figure Revenue Market Share (%) of ALL Vaccine by Type in 2016
Table EMEA ALL Vaccine Sale Price (USD/Unit) by Type (2012-2017)
Table EMEA ALL Vaccine Sales (K Units) and Market Share (%) by Application (2012-2017)
Table EMEA ALL Vaccine Sales Market Share (%) by Application (2012-2017)
Figure Sales Market Share (%) of ALL Vaccine by Application (2012-2017)
Figure EMEA ALL Vaccine Sales Market Share (%) by Application in 2016
Table EMEA ALL Vaccine Sales (K Units) and Market Share (%) by Regions (2012-2017)
Table EMEA ALL Vaccine Sales Market Share (%) by Regions (2012-2017)
Figure Sales Market Share (%) of ALL Vaccine by Regions (2012-2017)
Figure EMEA ALL Vaccine Sales Market Share (%) in 2016
Table EMEA ALL Vaccine Revenue (Million USD) and Market Share (%) by Regions (2012-2017)
Table EMEA ALL Vaccine Revenue Market Share (%) by Regions (2012-2017)
Figure Revenue Market Share (%) of ALL Vaccine by Regions (2012-2017)
Figure EMEA ALL Vaccine Revenue Market Share (%) Regions in 2016
Table EMEA ALL Vaccine Sales Price (USD/Unit) by Regions (2012-2017)
Figure Europe ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Europe ALL Vaccine Revenue (Million USD) and Growth Rate (%) (2012-2017)
Table Europe ALL Vaccine Sales (K Units) by Type (2012-2017)
Table Europe ALL Vaccine Sales Market Share (%) by Type (2012-2017)
Figure Europe ALL Vaccine Sales Market Share (%) by Type in 2016
Table Europe ALL Vaccine Sales (K Units) by Applications (2012-2017)
Table Europe ALL Vaccine Market Share (%) by Applications (2012-2017)
Figure Europe ALL Vaccine Market Share (%) by Applications in 2016
Table Europe ALL Vaccine Sales (K Units) by Countries (2012-2017)
Table Europe ALL Vaccine Sales Market Share (%) by Countries (2012-2017)
Figure Europe ALL Vaccine Sales Market Share (%) by Countries (2012-2017)
Figure Europe ALL Vaccine Sales Market Share (%) by Countries in 2016
Table Europe ALL Vaccine Revenue (Million USD) by Countries (2012-2017)
Table Europe ALL Vaccine Revenue Market Share (%) by Countries (2012-2017)
Figure Europe ALL Vaccine Revenue Market Share (%) by Countries (2012-2017)
Figure Europe ALL Vaccine Revenue Market Share (%) by Countries in 2016
Figure Germany ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure France ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure UK ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Russia ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Italy ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Benelux ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Middle East ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Middle East ALL Vaccine Revenue (Million USD) and Growth Rate (%) (2012-2017)
Table Middle East ALL Vaccine Sales (K Units) by Type (2012-2017)
Table Middle East ALL Vaccine Market Share (%) by Type (2012-2017)
Figure Middle East ALL Vaccine Market Share (%) by Type (2012-2017)
Table Middle East ALL Vaccine Sales (K Units) by Applications (2012-2017)
Table Middle East ALL Vaccine Market Share (%) by Applications (2012-2017)
Figure Middle East ALL Vaccine Sales Market Share (%) by Application in 2016
Table Middle East ALL Vaccine Sales (K Units) by Countries (2012-2017)
Table Middle East ALL Vaccine Sales Market Share (%) by Countries (2012-2017)
Figure Middle East ALL Vaccine Sales Market Share (%) by Countries in (2012-2017)
Figure Middle East ALL Vaccine Sales Market Share (%) by Countries in 2016
Table Middle East ALL Vaccine Revenue (Million USD) by Countries (2012-2017)
Table Middle East ALL Vaccine Revenue Market Share (%) by Countries (2012-2017)
Figure Middle East ALL Vaccine Revenue Market Share (%) by Countries (2012-2017)
Figure Middle East ALL Vaccine Revenue Market Share (%) by Countries in 2016
Figure Saudi Arabia ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Israel ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure UAE ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Iran ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Africa ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Africa ALL Vaccine Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa ALL Vaccine Sales (K Units) by Type (2012-2017)
Table Africa ALL Vaccine Sales Market Share (%) by Type (2012-2017)
Figure Africa ALL Vaccine Sales Market Share (%) by Type (2012-2017)
Figure Africa ALL Vaccine Sales Market Share (%) by Type in 2016
Table Africa ALL Vaccine Sales (K Units) by Applications (2012-2017)
Table Africa ALL Vaccine Sales Market Share (%) by Applications (2012-2017)
Figure Africa ALL Vaccine Sales Market Share (%) by Applications (2012-2017)
Table Africa ALL Vaccine Sales (K Units) by Countries (2012-2017)
Table Africa ALL Vaccine Sales Market Share (%) by Countries (2012-2017)
Figure Africa ALL Vaccine Sales Market Share (%) by Countries (2012-2017)
Figure Africa ALL Vaccine Sales Market Share (%) by Countries in 2016
Table Africa ALL Vaccine Revenue (Million USD) by Countries (2012-2017)
Table Africa ALL Vaccine Revenue Market Share (%) by Countries (2012-2017)
Figure Africa ALL Vaccine Revenue Market Share (%) by Countries (2012-2017)
Figure Africa ALL Vaccine Revenue Market Share (%) by Countries in 2016
Figure South Africa ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Nigeria ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Egypt ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Algeria ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Table Pfizer, Inc. Basic Information List
Table Pfizer, Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
Figure Pfizer, Inc. ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Pfizer, Inc. ALL Vaccine Sales Market Share (%) in EMEA (2012-2017)
Figure Pfizer, Inc. ALL Vaccine Revenue Market Share (%) in EMEA (2012-2017)
Table Glaxosmithkline, PLC. Basic Information List
Table Glaxosmithkline, PLC. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
Figure Glaxosmithkline, PLC. ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Glaxosmithkline, PLC. ALL Vaccine Sales Market Share (%) in EMEA (2012-2017)
Figure Glaxosmithkline, PLC. ALL Vaccine Revenue Market Share (%) in EMEA (2012-2017)
Table Merck & Co., Inc. Basic Information List
Table Merck & Co., Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
Figure Merck & Co., Inc. ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Merck & Co., Inc. ALL Vaccine Sales Market Share (%) in EMEA (2012-2017)
Figure Merck & Co., Inc. ALL Vaccine Revenue Market Share (%) in EMEA (2012-2017)
Table Novarits Basic Information List
Table Novarits ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
Figure Novarits ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Novarits ALL Vaccine Sales Market Share (%) in EMEA (2012-2017)
Figure Novarits ALL Vaccine Revenue Market Share (%) in EMEA (2012-2017)
Table Sanofi Pasteur Basic Information List
Table Sanofi Pasteur ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
Figure Sanofi Pasteur ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Sanofi Pasteur ALL Vaccine Sales Market Share (%) in EMEA (2012-2017)
Figure Sanofi Pasteur ALL Vaccine Revenue Market Share (%) in EMEA (2012-2017)
Table CSL Limited Basic Information List
Table CSL Limited ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
Figure CSL Limited ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure CSL Limited ALL Vaccine Sales Market Share (%) in EMEA (2012-2017)
Figure CSL Limited ALL Vaccine Revenue Market Share (%) in EMEA (2012-2017)
Table Emergent Biosolutions, Inc. Basic Information List
Table Emergent Biosolutions, Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
Figure Emergent Biosolutions, Inc. ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Emergent Biosolutions, Inc. ALL Vaccine Sales Market Share (%) in EMEA (2012-2017)
Figure Emergent Biosolutions, Inc. ALL Vaccine Revenue Market Share (%) in EMEA (2012-2017)
Table Johnson & Johnson Basic Information List
Table ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) Johnson & Johnson (2012-2017)
Figure Johnson & Johnson ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Johnson & Johnson ALL Vaccine Sales Market Share (%) in EMEA (2012-2017)
Figure Johnson & Johnson ALL Vaccine Revenue Market Share (%) in EMEA (2012-2017)
Table Medimmune, LLC. (A Subsidiary of Astrazeneca) Basic Information List
Table Medimmune, LLC. (A Subsidiary of Astrazeneca) ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
Figure Medimmune, LLC. (A Subsidiary of Astrazeneca) ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Medimmune, LLC. (A Subsidiary of Astrazeneca) ALL Vaccine Sales Market Share (%) in EMEA (2012-2017)
Figure Medimmune, LLC. (A Subsidiary of Astrazeneca) ALL Vaccine Revenue Market Share (%) in EMEA (2012-2017)
Table Astellas Pharma Inc. Basic Information List
Table Astellas Pharma Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)
Figure Astellas Pharma Inc. ALL Vaccine Sales (K Units) and Growth Rate (%) (2012-2017)
Figure Astellas Pharma Inc. ALL Vaccine Sales Market Share (%) in EMEA (2012-2017)
Figure Astellas Pharma Inc. ALL Vaccine Revenue Market Share (%) in EMEA (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of ALL Vaccine
Figure Manufacturing Process Analysis of ALL Vaccine
Figure ALL Vaccine Industrial Chain Analysis
Table Raw Materials Sources of ALL Vaccine Major Manufacturers in 2016
Table Major Buyers of ALL Vaccine
Table Distributors/Traders List
Figure EMEA ALL Vaccine Sales (K Units) and Growth Rate (%) Forecast (2017-2022)
Figure EMEA ALL Vaccine Revenue (Million USD) and Growth Rate (%) Forecast (2017-2022)
Figure EMEA ALL Vaccine Price (USD/Unit) and Trend Forecast (2017-2022)
Table EMEA ALL Vaccine Sales (K Units) Forecast by Regions (2017-2022)
Figure EMEA ALL Vaccine Sales Market Share (%) Forecast by Regions (2017-2022)
Table EMEA ALL Vaccine Revenue (Million USD) Forecast by Regions (2017-2022)
Figure EMEA ALL Vaccine Revenue Market Share (%) Forecast by Regions (2017-2022)
Table Europe ALL Vaccine Sales Forecast by Countries (2017-2022)
Figure Europe ALL Vaccine Sales Market Share (%) Forecast by Countries (2017-2022)
Table Europe ALL Vaccine Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe ALL Vaccine Revenue Market Share (%) Forecast by Countries (2017-2022)
Table Middle East ALL Vaccine Sales Forecast by Countries (2017-2022)
Figure Middle EastALL Vaccine Sales Market Share (%) Forecast by Countries (2017-2022)
Table Middle East ALL Vaccine Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East ALL Vaccine Revenue Market Share (%) Forecast by Countries (2017-2022)
Table Africa ALL Vaccine Sales Forecast by Countries (2017-2022)
Figure Africa ALL Vaccine Sales Market Share (%) Forecast by Countries (2017-2022)
Table Africa ALL Vaccine Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa ALL Vaccine Revenue Market Share (%) Forecast by Countries (2017-2022)
Table EMEA ALL Vaccine Sales Forecast by Type (2017-2022)
Figure EMEA ALL Vaccine Sales Market Share (%) Forecast by Type (2017-2022)
Table EMEA ALL Vaccine Sales Forecast by Application (2017-2022)
Figure EMEA ALL Vaccine Sales Market Share (%) Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources



Refer to Data Table Tab
This report studies the ALL Vaccine market status and outlook of EMEA and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in EMEA and major countries, and splits the ALL Vaccine market by product type and applications/end industries.

The global ALL Vaccine market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

EMEA also play important roles in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of XX. EMEA will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

Geographically, this report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of ALL Vaccine in these regions, from 2012 to 2022 (forecast), covering
Europe covers Germany, France, UK, Russia, Italy and Benelux;
Middle East includes Saudi Arabia, Israel, UAE and Iran;
Africa includes South Africa, Nigeria, Egypt and Algeria.

The major players/manufacturers in EMEA market include Pfizer, Inc., Glaxosmithkline, PLC., Merck & Co., Inc., Novarits, Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Inc., Johnson & Johnson, Medimmune, LLC. (A Subsidiary of Astrazeneca), Astellas Pharma Inc., Mitsubishi Tanabe, Dynavax Technologies, Novavax,


On the basis of product, the ALL Vaccine market is primarily split into
Vaccinia
Measles, mumps, rubella
Varicella
Influenza
Rotavirus
Zoster
Yellow Fever
Polio
Hepatitis A
Rabies
BCG
Diphtheria, tetanus
Hepatitis B
Haemophilus influenzae type b
Pertussis
Human papillomavirus
Meningococcal
Pneumococcal



On the basis on the end users/applications, this report covers
For Adult
For Child